Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates by cleaving TFIIA
Hidetaka Niizuma, … , Emily H. Cheng, James J. Hsieh
Hidetaka Niizuma, … , Emily H. Cheng, James J. Hsieh
Published June 22, 2021
Citation Information: JCI Insight. 2021;6(15):e149382. https://doi.org/10.1172/jci.insight.149382.
View: Text | PDF
Research Article Development Stem cells

Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates by cleaving TFIIA

  • Text
  • PDF
Abstract

Taspase1, a highly conserved threonine protease encoded by TASP1, cleaves nuclear histone-modifying factors and basal transcription regulators to orchestrate diverse transcription programs. Hereditary loss-of-function mutation of TASP1 has recently been reported in humans as resulting in an anomaly complex syndrome, which manifests with hematological, facial, and skeletal abnormalities. Here, we demonstrate that Taspase1-mediated cleavage of TFIIAα-β, rather than of MLL1 or MLL2, in mouse embryos was required for proper fetal liver hematopoiesis and correct segmental identities of the axial skeleton. Homozygous genetic deletion of Taspase1 disrupted embryonic hematopoietic stem cell self-renewal and quiescence states and axial skeleton fates. Strikingly, mice carrying knockin noncleavable mutations of TFIIAα-β, a well-characterized basal transcription factor, displayed more pronounced fetal liver and axial skeleton defects than those with noncleavable MLL1 and MLL2, 2 trithorax group histone H3 trimethyl transferases. Our study offers molecular insights into a syndrome in humans that results from loss of TASP1 and describes an unexpected role of TFIIAα-β cleavage in embryonic cell fate decisions.

Authors

Hidetaka Niizuma, Adam C. Searleman, Shugaku Takeda, Scott A. Armstrong, Christopher Y. Park, Emily H. Cheng, James J. Hsieh

×

Figure 1

Taspase1 deficiency results in fetal liver hematopoietic stem cell defects.

Options: View larger image (or click on image) Download as PowerPoint
Taspase1 deficiency results in fetal liver hematopoietic stem cell defec...
(A) Body weight and cell numbers of fetal livers (FLs) normalized to body weight of E14.5 embryos of the indicated WT and Taspase1-knockout (Tasp1–/–) embryos. Boxes contain the 25th to 75th percentiles of data sets, with 50th percentile center lines, and whiskers mark the 5th and 95th percentiles. Outliers are shown by dots. (B) Images of E14.5 FLs of the indicated genotypes. Scale bar: 2 mm. (C) Frequency of E14.5 FL cells committed to erythroid (TER-119+), myeloid (Gr-1+), and B cell (B220+) lineages. (D) Progenitor and stem cell analyses of E14.5 FL cells by flow cytometry. Lin–Sca-1+c-Kit+ cells are defined as LSK, and Lin–Sca-1–c-Kit+ cells as myeloid progenitors. Myeloid progenitors are subdivided into CMP, GMP, and MEP by CD34 and CD16/32. LSK CD150+ cells are defined as HSCs. (E) Quantification of stem and progenitor cells of 15 WT and 12 Tasp1–/– FLs. (F) HSCs per E14.5 FL of the indicated genotypes. Numbers were calculated by multiplying FL cellularity and HSC frequency. Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by Mann-Whitney U test. HSC, hematopoietic stem cell; CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; MEP, megakaryocyte-erythrocyte progenitor.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts